John Newman WJB
Since 2011, John Newman has served as the Senior Biotech and Special Pharmaceuticals Analyst for Citadel Securities. In this capacity, John Newman is responsible for overseeing the coverage of nine companies, a role he assumed within just three months of joining the company. He then disseminates data gathered through the compilation and distribution of research reports. Before joining Citadel Securities, Mr. Newman served as Director and Senior Analyst of Specialty Pharmaceuticals for Oppenheimer. Between 2008 and 2010, Mr. Newman was responsible for the coverage of nearly 30 stocks. Prior to starting his work with Oppenheimer, Mr. Newman spent three years at Merrill Lynch as an Associate Analyst on a biotechnology team. With a focus on oncology related businesses, Mr. Newman provided company reports, upheld models, and discussed company coverage with clients. Prior to launching his career, John Newman earned his Bachelor of Science from Loyola University in Chicago, Illinois, where he studied Chemistry. While attending the school, Mr. Newman served as the Treasurer for the American Chemical Society. He also participated in the school?s mentoring program. Mr. Newman went on to receive his PhD from the University of Maryland. Over the course of his studies at the school, Mr. Newman published three scientific papers and remained active with the American Chemical Society. Mr. Newman then took up a postdoctoral fellowship at the University of Wisconsin. Dedicated to helping those in need, Mr. Newman provides support to March of Dimes, the Leukemia and Lymphoma Society, and the American Cancer Society. A dog enthusiast, Mr. Newman spends much of his time with his black labrador retriever named Bear. He also enjoys running and swimming. An avid patron of the arts, Mr. Newman attends the opera and the New York Philharmonic.
John Newman WJB john newman oppenheimer